SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Larry Liebman who wrote (5298)7/9/1998 4:42:00 PM
From: Henry Niman  Read Replies (1) of 9719
 
I haven't seen the OSI patent, but the press release mentions advances made in the late 80's. A few relevant points include:
The first non-polypeptide hormone receptor (glucocorticoid) was sequenced (by Ron Evans at Salk) in 1985. Shortly thereafter, several additional receptors were sequenced which quickly defined hormone binding and DNA binding domains. Small molecules (tretinoin - active ingredient in Retin-A and isotretinoin - active ingredient in Accutane) that interacted with the hormone binding domain had been studied since the 70's.

When Ligand exclusively licensed Ron Evan's intracellular technology from Salk in 1988, the co-transfection assay was well established. Its function was to screen small molecules that affected transcription factors which controlled gene expression.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News